WNT16 and cancer: To determine whether frequently mutated WNT regulators, or those identified as putative cancer drivers, is relevant to patient outcome, we performed survival analysis on patients with cancers bearing mutations in the five most frequently mutated WNT signaling regulators (RNF43, KMT2D, TRRAP, APC, CREBBP) and those identified by driver analysis (MEN1, GNG12, WNT16, AXIN1, AXIN2, ZNRF3, SOX9, BCL9L, PYGO2 and WNT11).